Please login to the form below

Not currently logged in

HIV drug royalties sold for $160m

Vertex Pharmaceuticals has sold its rights to future royalties for two HIV drugs to GlaxoSmithKline
Vertex Pharmaceuticals has sold its rights to future royalties for two HIV drugs to GlaxoSmithKline (GSK).

Under the terms of the one-time cash payment, Vertex will not receive any royalties for future sales of HIV drugs Lexiva and Agenerase.

"The sale of this non-core financial asset provides us with significant capital and strengthens our financial position to support investment into key programs and future initiatives for our business," said Ian Smith, executive vice president and chief financial officer of Vertex Pharmaceuticals.

"In particular, this transaction will provide us with additional capital to support and advance our leadership position in hepatitis C drug development."

Vertex reported at the annual meeting of the European Association for the Study of the Liver (EASL) in April 2008 that results from early trials show that its hepatitis C drug, Telaprevir, used in combination with two other drugs, is a promising therapy.

6th June 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...